Caribou, MaxCyte enter CRISPR license agreement

By The Science Advisory Board staff writers

May 7, 2020 -- Caribou Biosciences and MaxCyte have announced a clinical and commercial license agreement for the development of Carbiou's CAR-T cell therapy program.

Under the agreement, Caribou gains rights to the use of MaxCyte's Flow Electroporation technology and ExPert platform for advancement of its CRISPR gene-edited allogenic T-cell therapy. Caribou will obtain nonexclusive clinical and commercial rights to the platform and in return MaxCyte will receive undisclosed development and approval milestones and sales-based payments in addition to licensing fees.
Copyright © 2020

International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter